Ralph Sharman, MD
Family Medicine · Dripping Springs, TXNPI 1548297096
Payments from drug & device makers
Across 375 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$869
- GSK$858
- AstraZeneca$632
- Lilly USA, LLC$558
- Pfizer$502
- Novo Nordisk$395
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,604100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $869 |
| GSK | 56 | $858 |
| AstraZeneca | 29 | $632 |
| Lilly USA, LLC | 35 | $558 |
| Pfizer | 29 | $502 |
| Novo Nordisk | 21 | $395 |
| Boehringer Ingelheim | 14 | $296 |
| Abbott | 12 | $280 |
| Amgen | 13 | $232 |
| Astellas Pharma US Inc | 13 | $232 |
| Bausch Health US, LLC | 12 | $217 |
| Johnson & Johnson | 10 | $206 |
| Exact Sciences | 7 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $130 |
| Bayer | 6 | $118 |
| CMP Pharma, Inc. | 2 | $84 |
| Esperion Therapeutics, Inc. | 5 | $82 |
| Novartis | 5 | $78 |
| Dexcom, Inc. | 3 | $77 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Amarin Pharma, Inc. | 5 | $73 |
| Medtronic | 3 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Noven Therapeutics, LLC | 2 | $39 |
| Merck | 3 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Genentech USA, Inc. | 2 | $34 |
| Antares Pharma, Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $23 |
| Corium, LLC | 1 | $23 |
| Cranial Technologies, Inc | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $13 |
How this compares
$6,604 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $121,617 |
| JardianceEmpagliflozin | 95 | $93,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $63,529 |
| EliquisApixaban | 46 | $57,160 |
| MounjaroTirzepatide | 44 | $51,590 |
| XareltoRivaroxaban | 53 | $42,609 |
| JanuviaSitagliptin Phosphate | 35 | $41,411 |
| TrulicityDulaglutide | 11 | $29,752 |
| InvokanaCanagliflozin | 27 | $20,258 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $16,758 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $13,765 |
| MyrbetriqMirabegron | 15 | $13,045 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $12,947 |
| FarxigaDapagliflozin Propanediol | 15 | $12,485 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $11,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $395 | $121,617115 claims |
| Boehringer IngelheimJardiance | $296 | $93,28995 claims |
| Lilly USA, LLCMounjaro, Trulicity | $558 | $81,34255 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $858 | $77,294106 claims |
| Johnson & JohnsonXarelto, Invokana | $206 | $62,86780 claims |
| PfizerEliquis, Paxlovid | $502 | $60,01864 claims |
| MerckJanuvia, Janumet Xr | $36 | $58,16956 claims |
| AstraZenecaFarxiga, Symbicort | $632 | $19,02537 claims |
| Astellas Pharma US IncMyrbetriq | $232 | $13,04515 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $6,042550 claims |
| AbbVieSynthroid | $869 | $1,57432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dripping Springs
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.